Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

It is with great pleasure that we present the latest edition of touchREVIEWS in Oncology & Haematology. This issue reflects the growing momentum of precision oncology, from liquid biopsy and response-adapted strategies to antibody–drug conjugates (ADCs) and immune-based therapies, alongside the challenges of translating these advances into routine, equitable care. We open with an editorial […]

An independent medical education grant from Coherus Oncology, Inc.
These activities are jointly provided by USF Health and touchIME.

Latest Activities

Downloads

Activities
Downloads
Activity 3

Immunotherapy in R/M NPC: Interpreting the evidence and individualizing care

Learning Objectives
Launched Aug 20, 26
19 mins
Video 1 1 Video

Immunotherapy in R/M NPC: Interpreting the evidence and individualizing care

Expert insights on the use of ICIs in R/M NPC, including treatment individualization and latest evidence.
Activity 2

Applying patient and disease characteristics to guide R/M NPC treatment3

Learning Objectives
Launched Sep 24, 25
14 mins
Video 1 1 Video

Case 1: First-line treatment selection

Robert, 54, has been diagnosed with stage IVB, metastatic, EBV-negative nasopharyngeal carcinoma.
Experts discuss the factors guiding first-line treatment
10 mins
Video 2

Case 2: First- and second-line treatment selection

Jason, 63, has locally recurrent, unresectable, EBV-associated nasopharyngeal carcinoma, as well as grade-3 hearing loss and hypertension.
Experts discuss their choice of first- and second-line treatments
9 mins
Video 3

Case 3: Second-line treatment selection

Sandra, 49, has EBV-associated nasopharyngeal carcinoma that has progressed on first-line therapy. She also has the autoimmune disease systemic lupus erythematosus.
Experts discuss key treatment considerations
Activity 1

Updates in recurrent/metastatic nasopharyngeal carcinoma: The evolving role of immune checkpoint inhibitors

Learning Objectives
Launched Sep 26, 24
15 mins
1 Video

Updates in recurrent/metastatic nasopharyngeal carcinoma: The evolving role of immune checkpoint inhibitors

Watch Prof. Barbara Burtness provide an update on the evolving role of ICIs in the management of RM-NPC.

Activity 2

Applying patient and disease characteristics to guide R/M NPC treatment

Launched Sep 24, 25

Expert Faculty4

Learn directly from experts in the field of Head and Neck Cancer

Prof. Barbara Burtness

Yale School of Medicine, New Haven, CT, USA
Close Popup

Prof. Barbara Burtness

Yale School of Medicine, New Haven, CT, USA

Biography

Dr. Deborah Wong

Dr Nabil Saba

Dr Nabil Saba

Winship Cancer Institute, Emory University, Atlanta, GA, USA
Close Popup

Dr Nabil Saba

Winship Cancer Institute, Emory University, Atlanta, GA, USA

Biography

Prof. Barbara Burtness

Dr Victoria Villaflor

Dr Victoria Villaflor

Chao Family Comprehensive Cancer Center, UCI Health, Orange, CA, USA
Close Popup

Dr Victoria Villaflor

Chao Family Comprehensive Cancer Center, UCI Health, Orange, CA, USA

Biography

Dr Nabil Saba

Dr. Deborah Wong

Dr. Deborah Wong

University of California, Los Angeles (UCLA), CA, USA
Close Popup

Dr. Deborah Wong

University of California, Los Angeles (UCLA), CA, USA

Biography

Dr Victoria Villaflor

Prof. Barbara Burtness

touchONCOLOGY touchONCOLOGY

Register now for FREE access to

  • 1000+ topical and insightful peer-reviewed journal articles
  • 100+ hours of bite-sized congress highlights
  • 10 major therapy areas packed with the latest scientific advances
  • 150+ specialties offering learn-on-the-go medical education
  • Concise email updates and newsletters so you never miss out

An independent medical education grant from Coherus Oncology, Inc.
These activities are jointly provided by USF Health and touchIME.

Close Popup

What You'll Learn

After completing this Program, you'll be better able to:
Select Activity...
View All
Activity 1
Activity 2
Activity 3
Activity 1

Updates in recurrent/metastatic nasopharyngeal carcinoma: The evolving role of immune checkpoint inhibitors

Learning Objective 1

Discuss the role of immune checkpoint inhibitors in the first-line setting for recurrent or metastatic nasopharyngeal carcinoma

Start Now
Learning Objective 2

Summarize the use of immune checkpoint inhibitors in the second- and subsequent-line treatment of recurrent or metastatic nasopharyngeal carcinoma

Start Now
Activity 2

Applying patient and disease characteristics to guide R/M NPC treatment

Learning Objective 1

Explain the guideline-recommended treatment options for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC)

Start Now
Learning Objective 2

Recall patient and disease characteristics that inform treatment selection in R/M NPC

Start Now
Learning Objective 3

Choose the most appropriate treatment for each patient with R/M NPC

Start Now
Activity 3

Immunotherapy in R/M NPC: Interpreting the evidence and individualizing care

Learning Objective 1

Apply current evidence and guidelines to inform treatment selection for patients with recurrent/metastatic nasopharyngeal carcinoma

Start Now
Learning Objective 2

Integrate patient- and disease-specific factors into individualized treatment decisions involving immunotherapy-based regimens

Start Now
Activity 1

Updates in recurrent/metastatic nasopharyngeal carcinoma: The evolving role of immune checkpoint inhibitors

Learning Objective 1

Discuss the role of immune checkpoint inhibitors in the first-line setting for recurrent or metastatic nasopharyngeal carcinoma

Start Now
Learning Objective 2

Summarize the use of immune checkpoint inhibitors in the second- and subsequent-line treatment of recurrent or metastatic nasopharyngeal carcinoma

Start Now
Activity 2

Applying patient and disease characteristics to guide R/M NPC treatment

Learning Objective 1

Explain the guideline-recommended treatment options for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC)

Start Now
Learning Objective 2

Recall patient and disease characteristics that inform treatment selection in R/M NPC

Start Now
Learning Objective 3

Choose the most appropriate treatment for each patient with R/M NPC

Start Now
Activity 3

Immunotherapy in R/M NPC: Interpreting the evidence and individualizing care

Learning Objective 1

Apply current evidence and guidelines to inform treatment selection for patients with recurrent/metastatic nasopharyngeal carcinoma

Start Now
Learning Objective 2

Integrate patient- and disease-specific factors into individualized treatment decisions involving immunotherapy-based regimens

Start Now